Medindia
Medindia LOGIN REGISTER
Advertisement

The global pharmacovigilance and drug safety software market size is expected to reach USD 207.7 million by 2024

Wednesday, June 27, 2018 Drug News
Advertisement
NEW YORK, June 27, 2018 /PRNewswire/ -- Pharmacovigilance and Drug Safety Software Market Size, Share & Trends Analysis Report By Functionality, By Delivery Mode, By End Use (Pharmaceutical & Biotech Companies, CROs, BPOs), And Segment Forecasts, 2018 - 2024 Read the full report: https://www.reportlinker.com/p05445414 The global pharmacovigilance and drug safety software market size is expected to reach USD 207.7 million by 2024 presenting a CAGR of 6.5% during the forecast period. Increasing number of adverse drug reactions (ADR) is a key factor for market growth. ADR imposes a significant burden on research organizations and companies. To curb this problem, pharmaceutical companies are opting for contract outsourcing of these services. Manufacturers are now striving to identify various ways of cost reduction and minimizing operational expenses by gradually shifting from being fully integrated pharmaceutical companies to sharing costs by collaborating with service providers.Outsourcing helps increase internal resource flexibility, improves timelines, and results in better outcomes in short as well as long terms. Outsourcing also helps achieve better pharmacovigilance (PV) through regulatory compliance, higher quality, better productivity, and improved strategic outcomes. PV service providers, in an attempt to ensure sustainability, are providing customized and end-to-end solutions to meet consumer needs.These firms are also incorporating integrated technologies such as electronic data capture and hosting of PV warehousing for aggregating cross industry data for benefit risk evaluation. Furthermore, the fact that service providers are now operating via a flexible and variable pricing structure and achieving operational excellence through constant product updates is expected to boost usage rates over the forecast period. Further key findings from the report suggest: • By functionality, fully integrated software solutions for pharmacovigilance are anticipated to reach USD 25.35 million by 2024, at a CAGR of 7.0% from 2016 to 2024. The ADR reporting software segment, on the other hand, is projected to ascend at a CAGR of 6.4% over the forecast period • Based on delivery mode, the on-demand segment dominated the global pharmacovigilance software market with a share of over 52.0% in 2015 • On the basis of end use, the CROs and BPO segments are slated to witness lucrative growth owing to increasing adoption by outsourcing companies to curb healthcare costs • The U.S. PV software market is anticipated to exceed USD 6.45 million by 2024. Asian countries, especially India and China, are also expected to observe remarkable growth in the coming years • The market is relatively competitive in nature thanks to presence of global multinational players. It is also consolidated to a certain extent • Some of the key companies in the market are United BioSource Corporation; Sparta Systems, Inc.; Oracle Corporation; Ennov Solutions Inc.; Max Application; EXTEDO GmbH; AB Cube; Relsys; Online Business Applications, Inc.; and ArisGlobal.Read the full report: https://www.reportlinker.com/p05445414 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement

Cision View original content:http://www.prnewswire.com/news-releases/the-global-pharmacovigilance-and-drug-safety-software-market-size-is-expected-to-reach-usd-207-7-million-by-2024--300673235.html

SOURCE Reportlinker

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close